Costacou T, Zgibor J C, Evans R W, Otvos J, Lopes-Virella M F, Tracy R P, Orchard T J
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Diabetologia. 2005 Jan;48(1):41-8. doi: 10.1007/s00125-004-1597-y. Epub 2004 Dec 23.
AIMS/HYPOTHESIS: Recent findings suggest the potential involvement of adiponectin in obesity, diabetes and cardiovascular disease. We assessed the prospective association between adiponectin concentration and coronary artery disease in individuals with type 1 diabetes.
Participants were identified from the Pittsburgh Epidemiology of Diabetes Complications cohort, a prospective follow-up study of childhood-onset type 1 diabetes. At baseline, subjects had a mean age of 28 years, and a mean diabetes duration of 19 years. Cases (determined by physician-diagnosed angina, confirmed myocardial infraction, stenosis >or=50%, ischemic ECG or revascularization) were matched to the control subjects with respect to sex, age and diabetes duration. Samples and risk factors for analyses were identified from the earliest exam prior to incidence in cases. Sera and information on all covariates were available for 28 cases and 34 control subjects. Proportional hazards models were constructed including matching variables.
Compared with those in men, adiponectin concentrations were elevated in females (p=0.009) and among individuals with macroalbuminuria (p=0.04). In multivariable analyses (adjusting for standard risk factors as well as lipoprotein measurements determined by nuclear magnetic resonance spectroscopy, E-selectin or antioxidants), adiponectin inversely predicted the incidence of coronary artery disease (hazard ratio=0.37 per 1 SD increase, 95% CI 0.19-0.73, p=0.004).
CONCLUSIONS/INTERPRETATION: The results suggest that increased adiponectin concentration is prospectively associated with a lower risk of coronary artery disease type 1 diabetes. The potential of adiponectin determination as a useful marker of, and potential therapeutic target for, coronary artery disease prevention in type 1 diabetes should be further explored.
目的/假设:最近的研究结果表明脂联素可能与肥胖、糖尿病和心血管疾病有关。我们评估了1型糖尿病患者脂联素浓度与冠状动脉疾病之间的前瞻性关联。
参与者来自匹兹堡糖尿病并发症流行病学队列,这是一项对儿童期发病的1型糖尿病进行的前瞻性随访研究。基线时,受试者的平均年龄为28岁,平均糖尿病病程为19年。病例(由医生诊断的心绞痛、确诊的心肌梗死、狭窄≥50%、缺血性心电图或血运重建确定)在性别、年龄和糖尿病病程方面与对照受试者匹配。分析的样本和危险因素从病例发病前的最早检查中确定。有28例病例和34例对照受试者的血清及所有协变量信息可用。构建了包括匹配变量的比例风险模型。
与男性相比,女性的脂联素浓度升高(p = 0.009),在大量白蛋白尿患者中也升高(p = 0.04)。在多变量分析中(调整标准危险因素以及通过核磁共振波谱、E选择素或抗氧化剂测定的脂蛋白测量值),脂联素反向预测冠状动脉疾病的发生率(每增加1个标准差,风险比=0.37,95%置信区间0.19 - 0.73,p = 0.004)。
结论/解读:结果表明脂联素浓度升高与1型糖尿病患者患冠状动脉疾病的较低风险前瞻性相关。应进一步探索测定脂联素作为1型糖尿病患者冠状动脉疾病预防的有用标志物和潜在治疗靶点的潜力。